CRTC2

Across TCGA pan-cancer cohorts, CRTC2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CRTC2 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CRTC2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRTC2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

SKCM and BLCA are the cancer types where CRTC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →
BLCA	DFS	Median	II,III,IV	0.762	0.498	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CRTC2–SKCM (DFS)

Open the SKCM breakdown →